 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 17 concerning Summit Corporation plc (formerly VASTox plc)
|
-
Positive results from phase I clinical trial of SMT D002 for the treatment of Seborrhoea
(04/22/2008)
SMT D002 suppresses sebum levels by 90% in repeat-dose trial
Summit Corporation plc announced a positive outcome from its repeat-dose Phase I clinical trial of SMT D002, its candidate for the treatment of seborrhoea (excessive sebum production), a primary cause of acne.The study was conducted in 18 healthy ...
-
Summit's lead drug candidate enters phase II clinical trials
(01/17/2008)
Candidate targets sialorrhoea, a symptom of Parkinson's disease
Summit Corporation plc announced that is has started a Phase II proof of concept clinical trial of its small molecule drug candidate SMT D001 for the treatment of sialorrhoea.Sialorrhoea is a common and distressing symptom of Parkinson's disease ...
-
Summit plc begins phase I clinical trial in seborrhoea
(10/25/2007)
Summit Corporation plc announced the commencement of a Phase I clinical trial of SMT D002 for the treatment of seborrhoea (excessive sebum production), a symptom of Parkinson's disease and the primary cause of acne. The recruitment of 18 healthy ...
-
Zebrafish data supports new drug candidate moving into human clinical trials
(08/10/2007)
Data Form Part of a Successful Safety and Toxicity Filing to the UK's Regulatory Agency MHRA
Summit Corporation plc announced that, for the first time, data generated by its zebrafish technology platform about the safety and toxicity of potential drug candidates has formed part of a successful submission to the UK's Medicines and Healthcare ...
-
Summit is new name for VASTox
(07/24/2007)
Summit Corporation plc announced that the Company's name change from VASTox plc has been completed. The Company decided to change its name from VASTox to Summit following a period of growth and development that saw it both enhance its drug pipeline ...
-
VASTox prepares to commence next phase of clinical development for two neuro-disorder drug programmes
(05/29/2007)
VASTox plc is preparing to commence the next set of clinical trials in its two leading neuro-disorder programmes, which target two symptoms of Parkinson's disease. This development follows positive results from initial Phase I studies of the small ...
-
VASTox selects preclinical candidate in Duchenne Muscular Dystrophy programme
(05/10/2007)
VASTox plc announced that it has selected a candidate to enter into preclinical development in the Company's Duchenne Muscular Dystrophy ("DMD") drug discovery programme. VASTox has a unique therapeutic approach that targets the underlying cause of ...
-
VASTox identifiies novel compound that kill tubercolosis bacteria
(04/30/2007)
VASTox plc reports positive results in its tuberculosis ("TB") drug discovery programme. The Company has identified from its proprietary screening libraries several novel series' of small, drug-like molecules that show high levels of in vitro ...
-
VASTox granted key European patent for Zebrafish chemical genomics
(04/18/2007)
VASTox plc announced that the European Patent Office has granted a patent (EP1644733/Screening Methods Employing the Zebrafish and the Blood Brain Barrier), which significantly increases the value of the Company's zebrafish disease modelling and ...
-
VASTox gaint Duchenne Muscular Dystrophy patent
(04/16/2007)
VASTox plc announced that the US Patent Office has granted a patent (US Application No.10/089,928/Utrophin Gene Promoter) which provides additional protection to the Company's drug discovery programme in Duchenne Muscular Dystrophy (DMD). The ...
Additional information
Summit Corporation plc (formerly VASTox plc)
Abingdon, United Kingdom
Company
|
|
|
|
Top
